585 results about "Eye disease" patented technology

The invention relates to eye drops containing exosomes and a preparation method and application thereof, and belongs to the technical field of eye drop preparation, the eye drops comprise exosome freeze-dried powder, the exosome freeze-dried powder is prepared from the exosomes obtained after mesenchymal stem cells are treated with TNF-alpha and IFN-alpha, and a herba houttuyniae extract, the eye drops provided by the invention can inhibit the phenotype of macrophage M1 and promote the M1 to be converted into the phenotype of M2; human corneal cell proliferation, migration and damage repair are promoted; mouse cornea injury repair is accelerated; the eye drops can be used for treating xerophthalmia, conjunctivitis and keratitis, and can also be used for preventing eye diseases and relieving asthenopia; the eye drops disclosed by the invention contain the exosome obtained after the mesenchymal stem cells are treated by the TNF-alpha and the IFN-alpha, so that the anti-inflammatory ability is stronger; the mesenchymal stem cell exosome and the herba houttuyniae extract are stored in a freeze-dried form, so that the activity is stable, and the storage time is long; in addition, the cordate houttuynia is cooperated with the exosome, so that the effect playing time can be prolonged, and the use frequency is reduced.

The invention provides a method of reducing the severity of, or treating, thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

Described herein are methods of treating or reducing the severity of thyroid eye disease (TED), as well as antibodies that bind and inhibit signaling through the insulin-like growth factor receptor 1, useful in the methods.

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, and a preparation method therefor and the use thereof. The compound has good TSHR antagonism, and is used in the treatment of thyroid-associated conditions and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and in the preparation of a drug for treating such conditions or diseases.

The invention provides an eye control interaction method, device and system based on eye movement tracking, and relates to the technical field of data processing. The method comprises the following steps: collecting eye movement data and user feature data of a testee; the user feature data comprises age, pupil color and eye disease type; extracting eye movement feature data according to the eye movement data and the user feature data; generating brain activity state information of the testee according to the eye movement feature data, and determining an eye control instruction of the testee according to the brain activity state information, the eye movement feature data and the user feature data; and performing eye control interaction based on the eye control instruction. According to the method, the characteristics of brain activity states, eye diseases and the like possibly existing in different types of users can be considered, the user feature data are collected, feature extraction is carried out in combination with the eye movement data, and the eye movement feature data accurately reflecting the real eye movement intention of the user is obtained, so that the obtained eye control instruction is adaptive to different users; while the eye control interaction accuracy is improved, smoother and more natural interaction experience is brought to the user.

The present invention provides constructs comprising modified riboswitches to regulate expression of a transgene within a subject. Methods of treating a disease, specifically an eye disease, are also contemplated.

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, a preparation method therefor and the use thereof. The compound (I) has a good TSHR antagonistic effect, and is used for treating thyroid-associated disorders and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and for preparing drugs for such disorders or diseases.

The invention relates to a flavonoid active fraction of an Abelmoschi corolla, a preparation method and an application thereof, and belongs to the field of traditional Chinese pharmaceutics. A high-purity Abelmoschi corolla flavonoid active fraction is prepared, which is found to have better therapeutic activity for kidney disease, and especially have a significant therapeutic effect for diabetic kidney disease and lupus nephritis, or contrast-induced kidney injury and eye diseases. Meanwhile, the Abelmoschi corolla flavonoid active fraction described in the invention also has good safety.

The present disclosure provides a compound of formula H having excellent PDE4B inhibitory activity, and a pharmaceutical composition thereof and a use thereof. The compound provided by the present disclosure can be used for effectively treating PDE4-related diseases and disorders, including but not limited to inflammatory respiratory diseases, inflammatory bowel diseases, inflammatory joint diseases, inflammatory skin diseases, inflammatory eye diseases, and diseases or cancers of the peripheral or central nervous system.

The invention discloses a multi-task learning-based retinal vessel segmentation and analysis method and system, and relates to the technical field of medical image processing, and the method comprises the steps: introducing an EMCAD module into an R-Unet model, and carrying out the retinal vessel segmentation; designing an area percentage quantization function; a multi-task learning framework RetiVas-MTNet is constructed and is used for auxiliary diagnosis of eye diseases. The EMCAD module fuses a channel attention CAB mechanism and a space attention SAB mechanism: 1) generating a channel weight through adaptive maximum pooling and average pooling, and strengthening key channel features; (2) context connection of local features is established through large kernel convolution, and the space attention weight is calculated; according to the invention, the EMCAD module is introduced, so that the segmentation precision of the microvessels is improved; the blood vessel area percentage is quantitatively designed, so that the crossing from qualitative segmentation to quantitative diagnosis is realized; a multi-task learning framework RetiVas-MTNet provides a comprehensive solution for automatic diagnosis of eye diseases.

The invention discloses a visual conversion system, method and equipment for eye disease auxiliary diagnosis and a storage medium, and solves the problems of single function, high data dependence, large computing resource demand and weak interpretability in the field of eye disease auxiliary diagnosis in the prior art. The system comprises an input processing module, a visual transformer trunk, a hybrid expert layer, a decoder head and an output generation module. According to the visual conversion system for eye disease auxiliary diagnosis, various ophthalmology imaging modes can be processed, multiple tasks can be executed, and the input processing module, the visual transformer trunk, the mixed expert layer, the decoder head and the output generation module in the system cooperate to reduce calculation requirements and maintain accuracy at the same time; the expert is dynamically selected according to the complexity of the input image, it is ensured that different inputs can obtain optimal feature processing, accuracy and efficiency are both considered, a decoder structure can be customized according to the features of different tasks, and the output precision of each task is ensured.

The invention discloses an eye disease diagnosis system and method based on a lesion space structure relation, and belongs to the technical field of intelligent eye disease diagnos.The eye disease diagnosis system comprises a lesion significance enhancement module and a lesion visual distribution information fusion module; the method comprises the following steps of: firstly, obtaining the characteristics of an eye lesion pixel, further refining the saliency characteristics to obtain the characteristics of the eye lesion pixel, constructing an eye lesion graph, and finally obtaining a global distribution mode of a lesion area through pooling operation to complete the diagnosis of the eye disease. According to the eye disease diagnosis system and method provided by the invention, effective information can be provided for identification and diagnosis of different types of eye diseases, an accurate retinal disease diagnosis result can be obtained, dispersed pathological features in the fundus image and a global distribution mode of the dispersed pathological features can be comprehensively understood, the calculation speed of a network is accelerated, and the calculation cost is reduced.

Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof for treating thyroid eye disease (TED) are provided herein. Anti-IGF-1R antibodies and compositions described herein can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, by inhibiting the activity of IGF-1R with such antibodies and compositions.

The present invention relates to a nucleic acid sequence derived from a regulatory region of a human Lgr5 gene and having promoter activity in retina non-long-process cells. The invention also relates to an expression cassette or vector comprising the promoter, a viral particle or cell comprising the expression cassette or vector, and a pharmaceutical composition comprising the expression cassette or vector and the viral particle or cell. The invention also relates to the use of the expression cassette, vector, viral particle, cell or pharmaceutical composition in the treatment of eye diseases, especially diseases associated with retinal ganglion cell degeneration.

The present invention relates to an exogenous target gene expression cassette for delivering an exogenous target gene to the retina, in particular AIPL1 to retinal pigment epithelial cells and photoreceptor cells, comprising an IRBP enhancer sequence, a rhodopsin kinase (RK) promoter sequence and a CAG intron sequence, which are operatively linked, and an exogenous target gene. The present invention also relates to a recombinant adeno-associated viral vector comprising a viral capsid comprising a capsid protein or a capsid protein variant and a viral vector genome comprising an expression cassette encoding for specifically expressing an exogenous target gene in retinal pigment epithelial cells and photoreceptor cells. The recombinant adeno-associated virus vector can be used for relieving or treating retinal degenerative eye diseases by intravitreal administration or subretinal administration.

The present invention relates generally to compositions, formulations, and methods for immunotherapy and drug delivery, including the treatment of eye diseases such as dry eye disease (DED). In particular, the present invention relates to methods of producing exosomes from mesenchymal stem cells (MSC-Exos) and, optionally, loading said exosomes with one or more bioactive substances. The exosomes may be loaded using electroporation with one or more bioactive substances such as proteins, miRNAs, and / or siRNA. In specific embodiments, the exosomes, and / or one or more biological compounds derived from the exosomes, may be provided to an individual in need thereof, including as part of one or more compositions containing mesenchymal stem cells (MSCs). The individual in need thereof may be an individual having a medical disorder such as DED, immune disorders, cancer, and other disorders. Therefore, the compositions containing MSCs can be used for topical application to the eye. The compositions can contain MSCs, MSC-Exos, one or more MSC-derived biological compounds (e.g., growth factors, proteins, etc.).

Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be affected under gonioscopic control. Internal delivery may be controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

The invention relates to a photoreceptor cell specific bidirectional promoter and application thereof. Specifically, the invention relates to a novel photoreceptor cell specific bidirectional promoter, an expression cassette containing the bidirectional promoter, a vector, a viral particle, a cell and a pharmaceutical composition, and application of the bidirectional promoter to treatment of eye diseases, such as retinal diseases.

The present disclosure relates to methods of treatment of thyroid eye disease (TED) by administering a fusion protein, such as a fusion protein as defined herein, to subjects in need thereof. The disclosure provides treatment of pathophysiological parameters of TED, including both systemic and local pathophysiological parameters, whereby the disease is efficiently treated.

To provide a composition and a pharmaceutical composition each of which exhibits, while suppressing rapid degeneration of tissues caused by administration thereof, excellent regulatory activity for chemokine receptors and excellent medicinal effects on a posterior eye disease and the like.SOLUTION: Provided are a composition comprising a GAG derivative and a chemokine receptor activity regulator, and a pharmaceutical composition comprising the composition.SELECTED DRAWING: None

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

The invention relates to a construction method of a thyroid-related eye disease animal model, and belongs to the technical field of biology. The invention provides a thyroid-associated ophthalmopathy animal model construction method, which comprises: (1) separating and purifying in vitro peripheral blood collected from a thyroid-associated ophthalmopathy patient to obtain an exosome; and (2) injecting the exosome into a to-be-modeled animal to prepare the thyroid-associated ophthalmopathy animal model. According to the invention, exosomes are extracted from in-vitro peripheral blood of patients with thyroid-associated ophthalmopathy and are injected into animals, so that the thyroid-associated ophthalmopathy animal model with a plurality of pathological characteristics such as orbital tissue inflammatory response, fibrosis, orbital lesion, thyroid dysfunction and the like is successfully constructed; the method can be widely applied to pathological mechanism research of thyroid-related eye diseases and screening and evaluation of thyroid-related eye disease treatment drugs.

The invention discloses an ophthalmology AI intelligent ward control system and method based on voice interaction. The system comprises an anti-noise voice acquisition unit, a multi-modal identity verification unit, a specialized semantic analysis unit, a medical rule engine unit, a safety protection unit, a multi-modal feedback unit and a dynamic optimization unit. Medical equipment noise is filtered out through a microphone array and an adaptive beam forming technology, and an instruction is analyzed in combination with a dialect recognition engine; executing triple identity verification, and performing forced superposition authentication on the cognitive impairment patient; calling an ophthalmology knowledge base to identify the risk keyword and generate a structured instruction; dynamically regulating and controlling the environment according to the eye disease type, and intercepting violation settlement according to a medical insurance rule; precise equipment voice control is forbidden, and when an emergency keyword is triggered, an OCT image is pushed preferentially and is directly connected with a physician; a big-character highlight interface and tactile pulse feedback are provided for the visually impaired patient, and data are synchronized to the HIS system in real time; and the dynamic optimization unit continuously updates the knowledge base and the medical insurance model. According to the invention, the instruction identification precision, the medical safety and the service suitability of the ophthalmology ward are obviously improved.

The present invention relates to methods for treating or reducing the severity of thyroid eye disease. In particular, the present invention provides methods for treating or reducing the severity of thyroid eye disease in patients in need thereof comprising administering an IGF-1R antagonist antibody according to specific dosage regimens. Pharmaceutical compositions comprising the IGF-1R antagonist antibody for use in the methods are also described.

The invention belongs to the technical field of intelligent medical decision support systems, and discloses an intelligent medical decision model training method based on ophthalmologic surgery, which comprises the following steps: acquiring original ophthalmologic data of a patient and carrying out preliminary data processing to obtain a patient ophthalmologic data set; image data in the ophthalmology data set of the patient is analyzed, eye feature vectors are detected and extracted, eye conditions of the patient are preliminarily classified, and eye diseases are marked; extracting clinical feature vectors of non-image data in the ophthalmology data set of the patient, and performing multi-source data fusion on the clinical feature vectors and the eye feature vectors to obtain influence feature vectors; taking the influence feature vector as input, and training to obtain an ophthalmologic operation intelligent medical decision model; the prediction result of the intelligent medical decision-making model for the ophthalmologic operation is explained through an explainable tool, a model explanation and operation evaluation report is generated, the diagnosis accuracy is improved, and the explanation and personalized treatment capacity of the model are enhanced.

The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), or a symptom or aspect thereof, in subjects that have undergone prior treatment for TAO, TED, or GO, and either did not respond to said prior treatment or relapsed after said prior treatment. The invention also provides antibodies, or antigen binding fragments thereof, and pharmaceutical compositions useful in the disclosed methods.

The invention provides a thyroid-related eye disease intraorbital soft tissue volume measurement method and system, and is applied to the technical field of data processing. Three-dimensional medical image data and system abnormal state information are obtained, the three-dimensional medical image data comprise CT images and MRI images, and the system abnormal state information comprises artifacts, isolated noisy points and irregular boundaries; data preprocessing is carried out on the three-dimensional medical image data, standardized image data is generated, and the standardized image data is formed by carrying out ternary processing on spatial registration, noise suppression and gray level normalization; processing the standardized image data and the system abnormal state information to generate an initial segmentation mask; processing the initial segmentation mask to generate an optimized mask; processing the optimized mask and the three-dimensional medical image data to generate soft tissue volume data; and processing the soft tissue volume data, the system abnormal state information and the historical volume data to generate a volume dynamic change report.

The invention discloses an eye disease recognition method and system, a medium and equipment, and relates to the field of image recognition, and the method comprises the steps: constructing a symptom recognition model based on improved ResNext50; in the improved ResNext50, a convolution layer of an original ResNext50 model is replaced by grouping depth separable convolution, a classification head of an original global average pooling and full connection layer is replaced by a feature fusion structure based on a multi-scale pyramid, and a space-channel double-attention mechanism is added at the tail end of a residual branch of an original Bottleneck structure; and carrying out positioning and focusing processing on a to-be-identified eye image, carrying out classification identification on the positioned and focused eye image through the trained symptom identification model, and obtaining an eye disease identification result.